Risk of Alzheimer's disease is not increased among patients with hidradenitis suppurativa: A retrospective population-based cohort analysis
To the Editor: Familial hidradenitis suppurativa (HS) and Alzheimer's disease (AD) have been linked to mutations in the -secretase complex. 1 In the brain, -secretase cleaves amyloid precursor protein, which results in the development of -amyloid plaques responsible for the development of AD. Genetic inactivation of -secretase in mouse skin also produces epidermal and follicular histologic abnormalities resembling those in HS that are thought to arise from alterations in Notch signaling. 2 Gamma secretase was also established as the genetic basis of disease for a subset of familial HS. 1 Given these genetic links, we evaluated the association between HS and AD in a retrospective cohort study. We used a data analytics and research platform that sources clinical data from 27 health systems mapped to the single set of Unified Medical Language System ontologies to create longitudinal records for a heterogeneous group of [48 million unique patients in the United States. 3 The Systematized Nomenclature of Medicine-Clinical Terms ''hidradenitis'' and ''Alzheimer's disease,'' which have one-to-one mapping with the International Classification of Diseases, 9th revision codes for HS (705.83) and AD (331.0), were used to identify patients. This methodology has been validated previously for both conditions. 4, 5 The study population included all patients with an active status in the database within the past 5 years and nonmissing sex and race information. Patients \40 years of age were excluded, given the rarity of AD in persons under this age. To ensure that our analysis captured individuals with newly diagnosed AD, patients with a diagnosis of AD before to the study start date were excluded. In addition, patients with an HS diagnosis occurring after a diagnosis of AD were excluded to ensure that the exposure of interest occurred before the outcome. The primary outcome of interest was diagnosis of AD. Age and sex were included as covariates. We obtained populationlevel counts of the number of patients with a firstever diagnosis of AD between 2012 and 2016 for each combination of categorical predictor variables (HS status, age, and sex). We also recorded groupspecific counts of patients with no AD diagnosis during the study period.
The characteristics of the HS cohort are described in Table I 
Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
To the Editor: Atopic dermatitis affects up to 25% of children and 2%-3% of adults worldwide. 1 Current systemic therapies for chronic, severe, and recalcitrant disease exist, including phototherapy, systemic corticosteroids, cyclosporine, methotrexate, azathioprine, and mycophenolate. 2 Although they are effective, close laboratory monitoring and inconvenience have limited their widespread use. Apremilast is an oral phosphodiesterase-4 (PDE-4) inhibitor proven effective for psoriasis vulgaris and psoriatic arthritis, but its use in atopic dermatitis has rarely been reported. 3 We present here the successful use of apremilast for 4 patients with chronic, severe atopic dermatitis, and a fifth patient with severe acral eczematous dermatitis.
Five patients were included; 3 patients fit the diagnostic criteria for atopic dermatitis. The other 2 patients had confirmatory skin biopsies showing spongiotic dermatitis. Patient characteristics are detailed in Table I . Severe pruritus was a common feature associated with their skin manifestations. Before starting apremilast, patients received extensive treatment that included oral prednisone, methotrexate, narrowband ultraviolet B, azathioprine, topical corticosteroids, calcineurin inhibitors, hydroxyzine, and coal tar with unsatisfactory results (Table I) .
All of our patients expressed concerns about the short-term and long-term adverse effects of systemic anti-inflammatory therapies. The decision was made to begin treatment with apremilast 30 mg twice daily using the standard titration as provided in the package insert. Within 2-4 weeks of initiating apremilast, all of the patients reported noticeable improvement in erythema, scaling, and xerosis of skin lesions (Fig 1) . All patients noted significant improvement of associated pruritus. Using the physician's global assessment, 2 patients were judged to achieve [75% improvement of their atopic dermatitis (Table I) . Patient 5, who had Table I . Demographic characteristics for hidradenitis suppurativa and control patients
